Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.948
Neutral
RSI(14)
50.267
Neutral
STOCH(KDJ)(9,3,3)
24.147
Buy
ATR(14)
1.301
High Vlolatility
CCI(14)
-64.866
Neutral
Williams %R
67.027
Sell
TRIX(12,20)
0.005
Sell
StochRSI(14)
100.000
Buy
Phibro Animal Health Corp
PAHC37.640USD
+1.060+2.90%
Close 10/14, 16:00（ET）Quotes delayed by 15 min
1.53BMarket Cap
31.61P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Phibro Animal Health Corp
Currency: USD Updated: 2025-10-14Key Insights
The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Phibro Animal Health Corp's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
4
analysts
Hold
Current Rating
32.667
Target Price
-10.70%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Phibro Animal Health Corp Highlights
StrengthsRisks
Phibro Animal Health Corporation is a global diversified animal health and mineral nutrition company. It develops, manufactures and markets a range of products for food and companion animals, including poultry, swine, beef and dairy cattle, aquaculture and dogs. It markets approximately 750 product lines in over 80 countries to approximately 4,200 customers. It has three segments: Animal Health, Mineral Nutrition and Performance Products. Its Animal Health segment develops, manufactures and markets about 280 product lines, including antibacterials, anticoccidials and related products; nutritional specialty products; and vaccines. The Mineral Nutrition segment is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 32.55% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 1.30B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 40.30%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 40.30%.
Fairly Valued
The company’s latest PE is 31.60, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 21.46M shares, decreasing 9.96% quarter-over-quarter.
Held by John Hussman
Star Investor John Hussman holds 84.00K shares of this stock.
Financial Health
Currency: USD Updated: 2025-10-14The company's current financial score is 8.57, which is higher than the Pharmaceuticals industry's average of 7.77. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 378.70M, representing a year-over-year increase of 38.63%, while its net profit experienced a year-over-year increase of 2190.43%.
Score
Financials
5.88
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data
Quality of Earnings
8.46
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
8.49
Phibro Animal Health Corp's Company Valuation
Currency: USD Updated: 2025-10-14The company’s current valuation score is 7.86, which is higher than the Pharmaceuticals industry's average of 7.19. Its current P/E ratio is 31.60, which is 1089.02% below the recent high of 375.69 and 66.78% above the recent low of 10.50.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 44/173
No Data
Earnings Forecast
Currency: USD Updated: 2025-10-14The company’s current earnings forecast score is 6.00, which is lower than the Pharmaceuticals industry's average of 7.78. The average price target for Phibro Animal Health Corp is 34.00, with a high of 37.00 and a low of 27.00.
Score
Support & Resistance
No Data
Analyst Rating
Based on
4
analysts
Hold
Current Rating
32.667
Target Price
-10.70%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
170
Total
5
Median
8
Average
Company name
Ratings
Analysts
Phibro Animal Health Corp
PAHC
4
Biogen Inc
BIIB
36
Amgen Inc
AMGN
34
Vertex Pharmaceuticals Inc
VRTX
33
AbbVie Inc
ABBV
31
Eli Lilly and Co
LLY
31
1
2
3
...
34
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
No Data
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-10-14The company’s current price momentum score is 7.19, which is higher than the Pharmaceuticals industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 40.73 and the support level at 35.18, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
36.978
Buy
MA10
37.843
Sell
MA20
38.447
Sell
MA50
35.861
Buy
MA100
31.259
Buy
MA200
26.349
Buy
Institutional Confidence
Currency: USD Updated: 2025-10-14The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 5.59. The latest institutional shareholding proportion is 105.37%, representing a quarter-over-quarter increase of 2.95%. The largest institutional shareholder is The Vanguard, holding a total of 1.54M shares, representing 7.58% of shares outstanding, with 2.07% increase in holdings.
Score
Institutional Shareholding
No Data
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
Acadian Asset Management LLC
ExodusPoint Capital Management, LP
Dimensional Fund Advisors, L.P.
Geode Capital Management, L.L.C.
Castleknight Management LP
Nuveen LLC
1
2
Risk Assessment
Currency: USD Updated: 2025-10-14The company’s current risk assessment score is 5.68, which is higher than the Pharmaceuticals industry's average of 5.11. The company's beta value is 0.83. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.83
VaR
+3.87%
240-Day Maximum Drawdown
+36.96%
240-Day Volatility
+49.36%
Return
Best Daily Return
60 days
+19.44%
120 days
+19.44%
5 years
+31.81%
Worst Daily Return
60 days
-5.09%
120 days
-5.09%
5 years
-18.52%
Sharpe Ratio
60 days
+2.14
120 days
+3.46
5 years
+0.59
Risk Assessment
Maximum Drawdown
240 days
+36.96%
3 years
+41.42%
5 years
+68.12%
Return-to-Drawdown Ratio
240 days
+1.61
3 years
+1.71
5 years
+0.27
Skewness
240 days
+1.45
3 years
+1.99
5 years
+1.63
Volatility
Realised Volatility
240 days
+49.36%
5 years
+45.02%
Standardised True Range
240 days
+2.73%
5 years
+1.98%
Downside Risk-Adjusted Return
120 days
+874.44%
240 days
+874.44%
Maximum Daily Upside Volatility
60 days
+46.78%
Maximum Daily Downside Volatility
60 days
+30.03%
Liquidity
Average Turnover Rate
60 days
+0.74%
120 days
+0.67%
5 years
--
Turnover Deviation
20 days
+59.71%
60 days
+47.60%
120 days
+34.82%
Peer Comparison
Pharmaceuticals
Phibro Animal Health Corp
PAHC
7.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ligand Pharmaceuticals Inc
LGND
8.63 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Tarsus Pharmaceuticals Inc
TARS
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mckesson Corp
MCK
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
